AMEDISYS INC (AMED) Stock Fundamental Analysis
NASDAQ:AMED - Nasdaq - US0234361089 - Common Stock - Currency: USD
Overall AMED gets a fundamental rating of 5 out of 10. We evaluated AMED against 108 industry peers in the Health Care Providers & Services industry. While AMED belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. AMED is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
AMED had positive earnings in the past year.
AMED had a positive operating cash flow in the past year.
AMED had positive earnings in 4 of the past 5 years.
In the past 5 years AMED always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of AMED (2.02%) is better than 62.62% of its industry peers.
The Return On Equity of AMED (3.81%) is better than 61.68% of its industry peers.
AMED has a Return On Invested Capital of 10.19%. This is amongst the best in the industry. AMED outperforms 84.11% of its industry peers.
AMED had an Average Return On Invested Capital over the past 3 years of 9.73%. This is in line with the industry average of 8.12%.
The last Return On Invested Capital (10.19%) for AMED is above the 3 year average (9.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 3.81% | ||
| ROIC | 10.19% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
1.3 Margins
AMED has a Profit Margin of 1.84%. This is in the better half of the industry: AMED outperforms 64.49% of its industry peers.
In the last couple of years the Profit Margin of AMED has declined.
With an excellent Operating Margin value of 8.92%, AMED belongs to the best of the industry, outperforming 81.31% of the companies in the same industry.
In the last couple of years the Operating Margin of AMED has remained more or less at the same level.
Looking at the Gross Margin, with a value of 43.34%, AMED is in the better half of the industry, outperforming 70.09% of the companies in the same industry.
In the last couple of years the Gross Margin of AMED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.92% | ||
| PM (TTM) | 1.84% | ||
| GM | 43.34% |
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
2. Health
2.1 Basic Checks
AMED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
AMED has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AMED has been increased compared to 5 years ago.
The debt/assets ratio for AMED has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.81 indicates that AMED is not in any danger for bankruptcy at the moment.
The Altman-Z score of AMED (3.81) is better than 75.70% of its industry peers.
The Debt to FCF ratio of AMED is 1.76, which is an excellent value as it means it would take AMED, only 1.76 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.76, AMED belongs to the top of the industry, outperforming 85.98% of the companies in the same industry.
AMED has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
AMED has a Debt to Equity ratio of 0.30. This is in the better half of the industry: AMED outperforms 63.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 1.76 | ||
| Altman-Z | 3.81 |
ROIC/WACC1.18
WACC8.61%
2.3 Liquidity
AMED has a Current Ratio of 1.23. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of AMED (1.23) is worse than 64.49% of its industry peers.
AMED has a Quick Ratio of 1.23. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.23, AMED perfoms like the industry average, outperforming 45.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
AMED shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.47%.
The Earnings Per Share has been decreasing by -0.46% on average over the past years.
The Revenue has been growing slightly by 5.01% in the past year.
The Revenue has been growing slightly by 3.73% on average over the past years.
EPS 1Y (TTM)0.47%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%2.13%
Revenue 1Y (TTM)5.01%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%4.78%
3.2 Future
Based on estimates for the next years, AMED will show a small growth in Earnings Per Share. The EPS will grow by 7.50% on average per year.
Based on estimates for the next years, AMED will show a small growth in Revenue. The Revenue will grow by 5.54% on average per year.
EPS Next Y15.73%
EPS Next 2Y10.48%
EPS Next 3Y7.5%
EPS Next 5YN/A
Revenue Next Year5.26%
Revenue Next 2Y5.82%
Revenue Next 3Y5.54%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AMED is valuated rather expensively with a Price/Earnings ratio of 21.35.
AMED's Price/Earnings ratio is a bit cheaper when compared to the industry. AMED is cheaper than 67.29% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 29.75, AMED is valued a bit cheaper.
A Price/Forward Earnings ratio of 18.45 indicates a rather expensive valuation of AMED.
AMED's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AMED is cheaper than 65.42% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.44. AMED is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.35 | ||
| Fwd PE | 18.45 |
4.2 Price Multiples
AMED's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AMED is cheaper than 68.22% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AMED is valued cheaply inside the industry as 81.31% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.06 | ||
| EV/EBITDA | 11.43 |
4.3 Compensation for Growth
AMED's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AMED has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.36
PEG (5Y)N/A
EPS Next 2Y10.48%
EPS Next 3Y7.5%
5. Dividend
5.1 Amount
AMED does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
92
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners91.9%
Inst Owner Change6.29%
Ins Owners1.76%
Ins Owner Change5.28%
Market Cap3.01B
Analysts53.75
Price Target99.32 (7.96%)
Short Float %7.92%
Short Ratio5.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.07%
Min EPS beat(2)-15.99%
Max EPS beat(2)-10.15%
EPS beat(4)1
Avg EPS beat(4)-4.48%
Min EPS beat(4)-15.99%
Max EPS beat(4)9.21%
EPS beat(8)3
Avg EPS beat(8)-0.71%
EPS beat(12)6
Avg EPS beat(12)2.06%
EPS beat(16)8
Avg EPS beat(16)2.38%
Revenue beat(2)0
Avg Revenue beat(2)-2.04%
Min Revenue beat(2)-2.05%
Max Revenue beat(2)-2.02%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.05%
Max Revenue beat(4)0.13%
Revenue beat(8)1
Avg Revenue beat(8)-2.02%
Revenue beat(12)1
Avg Revenue beat(12)-2.87%
Revenue beat(16)1
Avg Revenue beat(16)-2.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-0.75%
EPS NQ rev (3m)-2.67%
EPS NY rev (1m)-0.14%
EPS NY rev (3m)-0.45%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)0.44%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.35 | ||
| Fwd PE | 18.45 | ||
| P/S | 1.28 | ||
| P/FCF | 14.06 | ||
| P/OCF | 13.59 | ||
| P/B | 2.66 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.43 |
EPS(TTM)4.31
EY4.68%
EPS(NY)4.99
Fwd EY5.42%
FCF(TTM)6.54
FCFY7.11%
OCF(TTM)6.77
OCFY7.36%
SpS71.7
BVpS34.64
TBVpS-4.9
PEG (NY)1.36
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 3.81% | ||
| ROCE | 12.9% | ||
| ROIC | 10.19% | ||
| ROICexc | 12.53% | ||
| ROICexgc | 635.86% | ||
| OM | 8.92% | ||
| PM (TTM) | 1.84% | ||
| GM | 43.34% | ||
| FCFM | 9.13% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
ROICexc(3y)10.87%
ROICexc(5y)12.42%
ROICexgc(3y)283.58%
ROICexgc(5y)337.19%
ROCE(3y)12.32%
ROCE(5y)14.48%
ROICexcg growth 3Y57.65%
ROICexcg growth 5Y52.31%
ROICexc growth 3Y-5.72%
ROICexc growth 5Y-4.31%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
F-Score7
Asset Turnover1.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 1.76 | ||
| Debt/EBITDA | 1.26 | ||
| Cap/Depr | 12.19% | ||
| Cap/Sales | 0.31% | ||
| Interest Coverage | 6.99 | ||
| Cash Conversion | 82.09% | ||
| Profit Quality | 495.69% | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z | 3.81 |
F-Score7
WACC8.61%
ROIC/WACC1.18
Cap/Depr(3y)21.03%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.47%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%2.13%
EPS Next Y15.73%
EPS Next 2Y10.48%
EPS Next 3Y7.5%
EPS Next 5YN/A
Revenue 1Y (TTM)5.01%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%4.78%
Revenue Next Year5.26%
Revenue Next 2Y5.82%
Revenue Next 3Y5.54%
Revenue Next 5YN/A
EBIT growth 1Y21.19%
EBIT growth 3Y-8.39%
EBIT growth 5Y3.2%
EBIT Next Year21.67%
EBIT Next 3Y11.94%
EBIT Next 5YN/A
FCF growth 1Y72.16%
FCF growth 3Y5.56%
FCF growth 5Y2%
OCF growth 1Y61.58%
OCF growth 3Y5.48%
OCF growth 5Y1.88%